Summary

Persistence Market Research has recently released a comprehensive report on the worldwide market for viral vector manufacturing. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.

Key Insights: Viral Vector Manufacturing Market

• Market Size (2024E): USD 879.8 million
• Projected Market Value (2031F): USD 2,917.2 million
• Global Market Growth Rate (CAGR 2024 to 2031): 18.7%

Viral Vector Manufacturing Market - Report Scope:

Viral vector manufacturing is critical in the development and production of gene therapies, vaccines, and cancer immunotherapies. The market caters to pharmaceutical companies, research institutions, and contract manufacturing organizations (CMOs), offering a range of vector types including adenoviral vectors, lentiviral vectors, adeno-associated viral (AAV) vectors, and retroviral vectors.

Market Growth Drivers:

The global viral vector manufacturing market is propelled by several key factors, including the increasing prevalence of genetic disorders and cancers, advancements in gene therapy technologies, and growing investment in biopharmaceutical R&D. Additionally, the approval of novel gene therapies and the rising demand for efficient vaccine production drive market expansion.

Market Restraints:

Despite promising growth prospects, the viral vector manufacturing market faces challenges related to high production costs, complex regulatory requirements, and scalability issues. Manufacturing complexities and the need for specialized infrastructure further impede market growth, especially for small-scale manufacturers and emerging biotech companies.

Market Opportunities:

The viral vector manufacturing market presents significant growth opportunities driven by technological innovations, strategic partnerships, and the expansion of production capacities. The integration of automation and single-use technologies enhances manufacturing efficiency and scalability. Furthermore, the growing focus on personalized medicine and the development of next-generation therapies create new avenues for market expansion.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the viral vector manufacturing market globally?
• Which vector types and applications are driving adoption across different healthcare settings?
• How are technological advancements and process innovations reshaping the competitive landscape of the market?
• Who are the key players contributing to the viral vector manufacturing market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global viral vector manufacturing market?

Competitive Intelligence and Business Strategy:

Leading players in the global viral vector manufacturing market, including Thermo Fisher Scientific Inc., Charles River, and NOVASEP, focus on innovation, process optimization, and strategic collaborations to gain a competitive edge. These companies invest in R&D to develop advanced manufacturing platforms, enhance vector yield and quality, and meet the growing demand for gene therapies and vaccines.

Key Companies Profiled:

• Thermo Fisher Scientific Inc
• Charles River
• (Cobra Biologics)
• NOVASEP
• uniQure N.V
• Waisman Biomanufacturing
• Creative Biogene
• GenScript Biotech Corporation
• Novartis AG
• Merck KGaA
• Takara Bio, Inc.
• FUJIFILM Diosynth Biotechnologies
• LONZA
• Danaher Corp. (Aldevron)
• Sirion Biotech GmbH
• AGC Biologics

Key Segments of Manufacturing of Viral Vector Industry Research

By Virus Type:
• Lentiviral Vectors
• Adenoviral Vectors
• Adeno-Associated Viral Vectors
• Retrovirus

By Expression System:
• Transient
• Stable

By Application:
• Gene Therapy
• Vaccines
• Cancer Therapy

By End User:
• Biotechnology Companies
• Pharmaceutical Companies
• Contract Research Organizations (CROs)
• Academic and Research Institutes

By Region:
• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa (MEA)

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Innovation / Development Trends
4. Key Inclusions
4.1. Product Adoption Analysis
4.2. Regulatory Scenario
4.3. PESTEL analysis
4.4. Porter’s Analysis
4.5. Key Promotional and Branding Strategies, By Manufacturers
4.6. Value Chain Analysis
5. COVID-19 Crisis Analysis
5.1. 2024 Market Scenario
5.2. COVID-19 and Impact Analysis
5.2.1. By Virus Type
5.2.2. By Expression System
5.2.3. By Application
5.2.4. By End User
5.2.5. By Region
6. Market Background
6.1. Macro-Economic Factors
6.1.1. Global GDP Growth Outlook
6.1.2. Global Healthcare Expenditure Outlook
6.1.3. Gloal Gene Therapy Market Outlook
6.2. Forecast Factors - Relevance & Impact
6.2.1. Increasing drug discovery
6.2.2. Rapid growth in the biotechnology and biopharmaceutical industries
6.2.3. Increasing R&D Research in Genetics and Viral Technology
6.2.4. Increasing Adoption of Gene therapy
6.2.5. Increasing R&D in vaccine development
6.3. Market Dynamics
6.3.1. Drivers
6.3.2. Restraints
6.3.3. Opportunity Analysis
7. Global Viral Vector Manufacturing Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2031
7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2031
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2031, By Virus Type
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis, By Virus Type, 2019-2023
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Virus Type, 2024-2031
8.3.1. Lentiviral Vectors
8.3.2. Adenoviral Vectors
8.3.3. Adeno-associated viral vectors (AAV)
8.3.4. Retrovirus
8.4. Market Attractiveness Analysis By Virus Type
9. Global Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2031, By Expression System
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Expression System, 2019-2023
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Expression System, 2024-2031
9.3.1. Transient
9.3.2. Stable
9.4. Market Attractiveness Analysis By Expression System
10. Global Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2031, By Application
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis, By Application, 2019-2023
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Application, 2024-2031
10.3.1. Gene Therapy
10.3.2. Vaccines
10.3.3. Cancer Therapy
10.3.4. Others
10.4. Market Attractiveness Analysis By Application
11. Global Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2031, By End User
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis By End User, 2019-2023
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2024-2031
11.3.1. Biopharmaceutical Companies
11.3.2. Academic & Research Institutes
11.3.3. Contract Research Organizations
11.3.4. Contract Manufacturing Organizations
11.4. Market Attractiveness Analysis By End User
12. Global Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2031, by Region
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2031
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. South Asia
12.3.5. East Asia
12.3.6. Oceania
12.3.7. Middle East & Africa
12.4. Market Attractiveness Analysis By Region
13. North America Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2031
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2031
13.3.1. By Country
13.3.1.1. U.S.
13.3.1.2. Canada
13.3.2. By Virus Type
13.3.3. By Expression System
13.3.4. By Application
13.3.5. By End User
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Virus Type
13.4.3. By Expression System
13.4.4. By Application
13.4.5. By End User
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. U.S. Viral Vector Manufacturing Market
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Virus Type
13.8.1.2.2. By Expression System
13.8.1.2.3. By Application
13.8.1.2.4. By End User
13.8.2. Canada Viral Vector Manufacturing Market
13.8.3. Introduction
13.8.4. Market Analysis and Forecast by Market Taxonomy
13.8.4.1. By Virus Type
13.8.4.2. By Expression System
13.8.4.3. By Application
13.8.4.4. By End User
14. Latin America Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2031
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2031
14.3.1. By Country
14.3.1.1. Brazil
14.3.1.2. Mexico
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Virus Type
14.3.3. By Expression System
14.3.4. By Application
14.3.5. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Virus Type
14.4.3. By Expression System
14.4.4. By Application
14.4.5. By End User
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. Brazil Viral Vector Manufacturing Market
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Virus Type
14.8.1.2.2. By Expression System
14.8.1.2.3. By Application
14.8.1.2.4. By End User
14.8.2. Mexico Viral Vector Manufacturing Market
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Virus Type
14.8.2.2.2. By Expression System
14.8.2.2.3. By Application
14.8.2.2.4. By End User
14.8.3. Argentina Viral Vector Manufacturing Market
14.8.4. Introduction
14.8.5. Market Analysis and Forecast by Market Taxonomy
14.8.5.1. By Virus Type
14.8.5.2. By Expression System
14.8.5.3. By Application
14.8.5.4. By End User
15. Europe Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2031
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2031
15.3.1. By Country
15.3.1.1. U.K.
15.3.1.2. Germany
15.3.1.3. Italy
15.3.1.4. France
15.3.1.5. Spain
15.3.1.6. Russia
15.3.1.7. Nordic Countries
15.3.1.8. BENELUX
15.3.1.9. Rest of Europe
15.3.2. By Virus Type
15.3.3. By Expression System
15.3.4. By Application
15.3.5. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Virus Type
15.4.3. By Expression System
15.4.4. By Application
15.4.5. By End User
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. U.K. Viral Vector Manufacturing Market
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Virus Type
15.8.1.2.2. By Expression System
15.8.1.2.3. By Application
15.8.1.2.4. By End User
15.8.2. Germany Viral Vector Manufacturing Market
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Virus Type
15.8.2.2.2. By Expression System
15.8.2.2.3. By Application
15.8.2.2.4. By End User
15.8.3. Italy Viral Vector Manufacturing Market
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Virus Type
15.8.3.2.2. By Expression System
15.8.3.2.3. By Application
15.8.3.2.4. By End User
15.8.4. France Viral Vector Manufacturing Market
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast by Market Taxonomy
15.8.4.2.1. By Virus Type
15.8.4.2.2. By Expression System
15.8.4.2.3. By Application
15.8.4.2.4. By End User
15.8.5. Spain Viral Vector Manufacturing Market
15.8.5.1. Introduction
15.8.5.2. Market Analysis and Forecast by Market Taxonomy
15.8.5.2.1. By Virus Type
15.8.5.2.2. By Expression System
15.8.5.2.3. By Application
15.8.5.2.4. By End User
15.8.6. Russia Viral Vector Manufacturing Market
15.8.6.1. Introduction
15.8.6.2. Market Analysis and Forecast by Market Taxonomy
15.8.6.2.1. By Virus Type
15.8.6.2.2. By Expression System
15.8.6.2.3. By Application
15.8.6.2.4. By End User
15.8.7. Nordic Countries Viral Vector Manufacturing Market
15.8.7.1. Introduction
15.8.7.2. Market Analysis and Forecast by Market Taxonomy
15.8.7.2.1. By Virus Type
15.8.7.2.2. By Expression System
15.8.7.2.3. By Application
15.8.7.2.4. By End User
15.8.8. BENELUX Viral Vector Manufacturing Market
15.8.8.1. Introduction
15.8.8.2. Market Analysis and Forecast by Market Taxonomy
15.8.8.2.1. By Virus Type
15.8.8.2.2. By Expression System
15.8.8.2.3. By Application
15.8.8.2.4. By End User
16. South Asia Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2031
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2031
16.3.1. By Country
16.3.1.1. India
16.3.1.2. Indonesia
16.3.1.3. Malaysia
16.3.1.4. Philippines
16.3.1.5. Thailand
16.3.1.6. Vietnam
16.3.1.7. Rest of South Asia
16.3.2. By Virus Type
16.3.3. By Expression System
16.3.4. By Application
16.3.5. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Virus Type
16.4.3. By Expression System
16.4.4. By Application
16.4.5. By End User
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. India Viral Vector Manufacturing Market
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Virus Type
16.8.1.2.2. By Expression System
16.8.1.2.3. By Application
16.8.1.2.4. By End User
16.8.2. Indonesia Viral Vector Manufacturing Market
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Virus Type
16.8.2.2.2. By Expression System
16.8.2.2.3. By Application
16.8.2.2.4. By End User
16.8.3. Malaysia Viral Vector Manufacturing Market
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Virus Type
16.8.3.2.2. By Expression System
16.8.3.2.3. By Application
16.8.3.2.4. By End User
16.8.4. Philippines Viral Vector Manufacturing Market
16.8.4.1. Introduction
16.8.4.2. Market Analysis and Forecast by Market Taxonomy
16.8.4.2.1. By Virus Type
16.8.4.2.2. By Expression System
16.8.4.2.3. By Application
16.8.4.2.4. By End User
16.8.5. Thailand Viral Vector Manufacturing Market
16.8.5.1. Introduction
16.8.5.2. Market Analysis and Forecast by Market Taxonomy
16.8.5.2.1. By Virus Type
16.8.5.2.2. By Expression System
16.8.5.2.3. By Application
16.8.5.2.4. By End User
16.8.6. Vietnam Viral Vector Manufacturing Market
16.8.6.1. Introduction
16.8.6.2. Market Analysis and Forecast by Market Taxonomy
16.8.6.2.1. By Virus Type
16.8.6.2.2. By Expression System
16.8.6.2.3. By Application
16.8.6.2.4. By End User
17. East Asia Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2031
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2031
17.3.1. By Country
17.3.1.1. China
17.3.1.2. Japan
17.3.1.3. South Korea
17.3.2. By Virus Type
17.3.3. By Expression System
17.3.4. By Application
17.3.5. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Virus Type
17.4.3. By Expression System
17.4.4. By Application
17.4.5. By End User
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. China Viral Vector Manufacturing Market
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Virus Type
17.8.1.2.2. By Expression System
17.8.1.2.3. By Application
17.8.1.2.4. By End User
17.8.2. Japan Viral Vector Manufacturing Market
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Virus Type
17.8.2.2.2. By Expression System
17.8.2.2.3. By Application
17.8.2.2.4. By End User
17.8.3. South Korea Viral Vector Manufacturing Market
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Virus Type
17.8.3.2.2. By Expression System
17.8.3.2.3. By Application
17.8.3.2.4. By End User
18. Oceania Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2031
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2031
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Virus Type
18.3.3. By Expression System
18.3.4. By Application
18.3.5. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Virus Type
18.4.3. By Expression System
18.4.4. By Application
18.4.5. By End User
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. Australia Viral Vector Manufacturing Market
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Virus Type
18.8.1.2.2. By Expression System
18.8.1.2.3. By Application
18.8.1.2.4. By End User
18.8.2. New Zealand Viral Vector Manufacturing Market
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Virus Type
18.8.2.2.2. By Expression System
18.8.2.2.3. By Application
18.8.2.2.4. By End User
19. Middle East and Africa Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2031
19.1. Introduction
19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2031
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. Turkey
19.3.1.3. Israel
19.3.1.4. Northern Africa
19.3.1.5. South Africa
19.3.1.6. Rest of Middle East and Africa
19.3.2. By Virus Type
19.3.3. By Expression System
19.3.4. By Application
19.3.5. By End User
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Virus Type
19.4.3. By Expression System
19.4.4. By Application
19.4.5. By End User
19.5. Market Trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country Level Analysis & Forecast
19.8.1. GCC Countries Viral Vector Manufacturing Market
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast by Market Taxonomy
19.8.1.2.1. By Virus Type
19.8.1.2.2. By Expression System
19.8.1.2.3. By Application
19.8.1.2.4. By End User
19.8.2. Turkey Viral Vector Manufacturing Market
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast by Market Taxonomy
19.8.2.2.1. By Virus Type
19.8.2.2.2. By Expression System
19.8.2.2.3. By Application
19.8.2.2.4. By End User
19.8.3. Israel Viral Vector Manufacturing Market
19.8.3.1. Introduction
19.8.3.2. Market Analysis and Forecast by Market Taxonomy
19.8.3.2.1. By Virus Type
19.8.3.2.2. By Expression System
19.8.3.2.3. By Application
19.8.3.2.4. By End User
19.8.4. South Africa Viral Vector Manufacturing Market
19.8.4.1. Introduction
19.8.4.2. Market Analysis and Forecast by Market Taxonomy
19.8.4.2.1. By Virus Type
19.8.4.2.2. By Expression System
19.8.4.2.3. By Application
19.8.4.2.4. By End User
19.8.5. North Africa Viral Vector Manufacturing Market
19.8.5.1. Introduction
19.8.5.2. Market Analysis and Forecast by Market Taxonomy
19.8.5.2.1. By Virus Type
19.8.5.2.2. By Expression System
19.8.5.2.3. By Application
19.8.5.2.4. By End User
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Share Analysis of Top Players
20.3. Market Presence Analysis
20.3.1. Regional Footprint of Players
20.3.2. Product Foot Print by Players
20.3.3. Channel Foot Print by Players
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive
21.3.1. Thermo Fisher Scientific Inc
21.3.1.1. Overview
21.3.1.2. Product Portfolio
21.3.1.3. Sales Footprint
21.3.1.4. Key Financials
21.3.1.5. SWOT Analysis
21.3.1.6. Strategy Overview
21.3.1.6.1. Marketing Strategy
21.3.1.6.2. Product Strategy
21.3.1.6.3. Channel Strategy
21.3.2. Charles River (Cobra Biologics)
21.3.2.1. Overview
21.3.2.2. Product Portfolio
21.3.2.3. Sales Footprint
21.3.2.4. Key Financials
21.3.2.5. SWOT Analysis
21.3.2.6. Strategy Overview
21.3.2.6.1. Marketing Strategy
21.3.2.6.2. Product Strategy
21.3.2.6.3. Channel Strategy
21.3.3. Novasep
21.3.3.1. Overview
21.3.3.2. Product Portfolio
21.3.3.3. Sales Footprint
21.3.3.4. Key Financials
21.3.3.5. SWOT Analysis
21.3.3.6. Strategy Overview
21.3.3.6.1. Marketing Strategy
21.3.3.6.2. Product Strategy
21.3.3.6.3. Channel Strategy
21.3.4. uniQure N.V.
21.3.4.1. Overview
21.3.4.2. Product Portfolio
21.3.4.3. Sales Footprint
21.3.4.4. Key Financials
21.3.4.5. SWOT Analysis
21.3.4.6. Strategy Overview
21.3.4.6.1. Marketing Strategy
21.3.4.6.2. Product Strategy
21.3.4.6.3. Channel Strategy
21.3.5. Waisman Biomanufacturing
21.3.5.1. Overview
21.3.5.2. Product Portfolio
21.3.5.3. Sales Footprint
21.3.5.4. Key Financials
21.3.5.5. SWOT Analysis
21.3.5.6. Strategy Overview
21.3.5.6.1. Marketing Strategy
21.3.5.6.2. Product Strategy
21.3.5.6.3. Channel Strategy
21.3.6. Creative Biogene
21.3.6.1. Overview
21.3.6.2. Product Portfolio
21.3.6.3. Sales Footprint
21.3.6.4. Key Financials
21.3.6.5. SWOT Analysis
21.3.6.6. Strategy Overview
21.3.6.6.1. Marketing Strategy
21.3.6.6.2. Product Strategy
21.3.6.6.3. Channel Strategy
21.3.7. GenScript Biotech Corporation
21.3.7.1. Overview
21.3.7.2. Product Portfolio
21.3.7.3. Sales Footprint
21.3.7.4. Key Financials
21.3.7.5. SWOT Analysis
21.3.7.6. Strategy Overview
21.3.7.6.1. Marketing Strategy
21.3.7.6.2. Product Strategy
21.3.7.6.3. Channel Strategy
21.3.8. Novartis AG
21.3.8.1. Overview
21.3.8.2. Product Portfolio
21.3.8.3. Sales Footprint
21.3.8.4. Key Financials
21.3.8.5. SWOT Analysis
21.3.8.6. Strategy Overview
21.3.8.6.1. Marketing Strategy
21.3.8.6.2. Product Strategy
21.3.8.6.3. Channel Strategy
21.3.9. Merck KGaA.
21.3.9.1. Overview
21.3.9.2. Product Portfolio
21.3.9.3. Sales Footprint
21.3.9.4. Key Financials
21.3.9.5. SWOT Analysis
21.3.9.6. Strategy Overview
21.3.9.6.1. Marketing Strategy
21.3.9.6.2. Product Strategy
21.3.9.6.3. Channel Strategy
21.3.10. Takara Bio Inc.
21.3.10.1. Overview
21.3.10.2. Product Portfolio
21.3.10.3. Sales Footprint
21.3.10.4. Key Financials
21.3.10.5. SWOT Analysis
21.3.10.6. Strategy Overview
21.3.10.6.1. Marketing Strategy
21.3.10.6.2. Product Strategy
21.3.10.6.3. Channel Strategy
21.3.11. FUJIFILM Diosynth Biotechnologies
21.3.11.1. Overview
21.3.11.2. Product Portfolio
21.3.11.3. Sales Footprint
21.3.11.4. Key Financials
21.3.11.5. SWOT Analysis
21.3.11.6. Strategy Overview
21.3.11.6.1. Marketing Strategy
21.3.11.6.2. Product Strategy
21.3.11.6.3. Channel Strategy
21.3.12. Lonza
21.3.12.1. Overview
21.3.12.2. Product Portfolio
21.3.12.3. Sales Footprint
21.3.12.4. Key Financials
21.3.12.5. SWOT Analysis
21.3.12.6. Strategy Overview
21.3.12.6.1. Marketing Strategy
21.3.12.6.2. Product Strategy
21.3.12.6.3. Channel Strategy
21.3.13. Danaher Corp. (Aldevron)
21.3.13.1. Overview
21.3.13.2. Product Portfolio
21.3.13.3. Sales Footprint
21.3.13.4. Key Financials
21.3.13.5. SWOT Analysis
21.3.13.6. Strategy Overview
21.3.13.6.1. Marketing Strategy
21.3.13.6.2. Product Strategy
21.3.13.6.3. Channel Strategy
21.3.14. Sirion-Biotech GmbH
21.3.14.1. Overview
21.3.14.2. Product Portfolio
21.3.14.3. Sales Footprint
21.3.14.4. Key Financials
21.3.14.5. SWOT Analysis
21.3.14.6. Strategy Overview
21.3.14.6.1. Marketing Strategy
21.3.14.6.2. Product Strategy
21.3.14.6.3. Channel Strategy
21.3.15. AGC Biologics
21.3.15.1. Overview
21.3.15.2. Product Portfolio
21.3.15.3. Sales Footprint
21.3.15.4. Key Financials
21.3.15.5. SWOT Analysis
21.3.15.6. Strategy Overview
21.3.15.6.1. Marketing Strategy
21.3.15.6.2. Product Strategy
21.3.15.6.3. Channel Strategy
22. Assumptions and Acronyms Used
23. Research Methodology